Nanobody CAR-T therapy takes on resistant lymphoma in early trial
NCT ID NCT07546630
First seen May 01, 2026 · Last updated May 10, 2026 · Updated 3 times
Summary
This early-phase study tests a new type of CAR-T cell therapy that uses nanobodies to target two markers (CD19 and CD20) on lymphoma cells. It aims to see if the treatment is safe and find the best dose in 20 people with relapsed or refractory B-cell lymphoma. The therapy is given as a one-time infusion, but patients may need ongoing monitoring for side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.